Results 11 to 20 of about 1,467,646 (404)

Bispecific antibody therapies. [PDF]

open access: yesHematology Am Soc Hematol Educ Program, 2023
Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis LH, Fassi DE, Hutchings M.
europepmc   +5 more sources

Design and Production of Bispecific Antibodies [PDF]

open access: yesAntibodies, 2019
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang   +7 more
doaj   +4 more sources

Bispecific antibodies for viral immunotherapy [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura   +2 more
doaj   +4 more sources

Production of native bispecific antibodies in rabbits. [PDF]

open access: yesPLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +5 more sources

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

open access: yesJournal for ImmunoTherapy of Cancer, 2020
Background Small cell lung cancer (SCLC) accounts for 15% of lung cancers, and the primary treatment of this malignancy is chemotherapy and radiotherapy.
Xin Chen   +7 more
doaj   +2 more sources

Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics [PDF]

open access: yesScientific Reports
ABL602 2 + 1, a bispecific antibody with two distinct domains binding to CLL-1 on leukemias and CD3 on T cells, exhibits superior T cell activation and tumour lysing activity.
Shilian Xu
doaj   +2 more sources

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

open access: yesJournal for ImmunoTherapy of Cancer, 2021
Background T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity in hematologic ...
Shahram Salek-Ardakani   +13 more
doaj   +2 more sources

Bispecific antibodies for cancer therapy [PDF]

open access: goldImmunotherapy, 2009
Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
Patrick Chames, Daniel Baty
openalex   +4 more sources

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.

open access: yesNew England Journal of Medicine, 2022
BACKGROUND G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing ...
A. Chari   +19 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy